PYXS Pyxis Oncology, Inc.
Nasdaq · SEC CIK 1782223 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $107.1K 1 sales by 1 insiders
- Filings on record
- 101 since 2021-10-12, latest 2026-09-08 07:41
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Dupont Jakob | Dir | — | $107.1K |
| Wadhane Jitendra | Prin Fin, Acct Off | — | — |
Transactions 63
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-07-02 16:30 | 2026-06-30 | PYXS | Dupont Jakob | Dir | M - OptEx | $1.60 | +35.0K | 73.7K | +90% | +$56.0K |
| DT | 2026-07-02 16:30 | 2026-06-30 | PYXS | Dupont Jakob | Dir | S - Sale+OE | $3.06 | -35.0K | 38.7K | -47% | -$107.1K |
| D | 2026-03-25 | 2026-03-24 | PYXS | Wadhane Jitendra | Prin Fin, Acct Off | A - Grant | $0.00 | +109.5K | 512.9K | +27% | $0 |
| MT | 2026-03-25 | 2025-04-14+ | PYXS | HUMPHREY RACHEL | Dir | S - Sale | $1.02 | -15.5K | 95.2K | -14% | -$15.9K |
| MI | 2024-11-27 | 2024-11-26 | PYXS | Connealy Pamela Ann | CFO, COO | P - Purchase | $1.96 | +88.8K | 1.20M | +8% | +$174.4K |
| 2024-06-07 | 2024-06-07 | PYXS | Palani Santhosh | Dir | A - Grant | $0.00 | +6,000 | 6,000 | New | $0 | |
| 2024-03-28 | 2024-03-26 | PYXS | Cline Darren S | Dir | A - Grant | $0.00 | +35.2K | 251.4K | +16% | $0 | |
| 2024-03-28 | 2024-03-26 | PYXS | Connealy Pamela Ann | CFO, COO | A - Grant | $0.00 | +328.7K | 1.11M | +42% | $0 | |
| 2024-03-28 | 2024-03-26 | PYXS | Dupont Jakob | Dir | A - Grant | $0.00 | +38.7K | 38.7K | New | $0 | |
| 2024-03-28 | 2024-03-26 | PYXS | FLAVIN JOHN L | Dir | A - Grant | $0.00 | +35.2K | 413.0K | +9% | $0 | |
| 2024-03-28 | 2024-03-26 | PYXS | HUMPHREY RACHEL | Dir | A - Grant | $0.00 | +38.7K | 96.8K | +67% | $0 | |
| 2024-03-28 | 2024-03-26 | PYXS | Wadhane Jitendra | SVP, CAO | A - Grant | $0.00 | +131.5K | 398.4K | +49% | $0 | |
| 2024-03-28 | 2024-03-26 | PYXS | Lewis-Hall Freda C | Dir | A - Grant | $0.00 | +35.2K | 241.4K | +17% | $0 | |
| 2023-11-30 | 2023-11-29 | PYXS | Connealy Pamela Ann | CFO, COO | F - Tax | $1.40 | -36.9K | 781.6K | -5% | -$51.7K | |
| 2023-11-17 | 2023-11-15 | PYXS | Wadhane Jitendra | CAO | A - Grant | $0.00 | +40.0K | 266.9K | +18% | $0 | |
| 2023-09-28 | 2023-09-28 | PYXS | Connealy Pamela Ann | CFO, COO | P - Purchase | $1.87 | +8,000 | 818.5K | +1.0% | +$15.0K | |
| 2023-09-27 | 2023-09-27 | PYXS | Wadhane Jitendra | CAO | P - Purchase | $1.87 | +2,500 | 226.9K | +1% | +$4,675 | |
| 2023-09-27 | 2023-09-27 | PYXS | Connealy Pamela Ann | CFO, COO | P - Purchase | $1.85 | +6,426 | 810.5K | +0.8% | +$11.9K | |
| 2023-09-25 | 2023-09-25 | PYXS | Wadhane Jitendra | CAO | P - Purchase | $1.77 | +5,000 | 224.4K | +2% | +$8,850 | |
| 2023-09-25 | 2023-09-25 | PYXS | Connealy Pamela Ann | CFO, COO | P - Purchase | $1.67 | +12.0K | 804.1K | +2% | +$20.0K | |
| 2023-09-22 | 2023-09-22 | PYXS | Connealy Pamela Ann | CFO, COO | P - Purchase | $1.74 | +5,000 | 792.1K | +0.6% | +$8,700 | |
| 2023-09-22 | 2023-09-22 | PYXS | Wadhane Jitendra | CAO | P - Purchase | $1.74 | +2,500 | 219.4K | +1% | +$4,350 | |
| M | 2023-09-18 | 2023-09-14+ | PYXS | Sullivan Lara | Pres, CEO, Dir | S - Sale | $2.10 | -8,641 | 2.40M | -0.4% | -$18.2K |
| M | 2023-09-13 | 2023-09-11+ | PYXS | Sullivan Lara | Pres, CEO, Dir | S - Sale | $2.27 | -27.9K | 2.60M | -1% | -$63.3K |
| 2023-09-13 | 2023-09-13 | PYXS | Sullivan Lara | Pres, CEO, Dir | F - Tax | $2.13 | -184.7K | 2.41M | -7% | -$393.5K | |
| 2023-09-08 | 2023-09-07 | PYXS | Sullivan Lara | Pres, CEO, Dir | A - Grant | $0.00 | +469.5K | 2.63M | +22% | $0 | |
| 2023-09-08 | 2023-09-07 | PYXS | Wadhane Jitendra | CAO | A - Grant | $0.00 | +93.9K | 211.9K | +80% | $0 | |
| 2023-09-08 | 2023-09-07 | PYXS | Connealy Pamela Ann | CFO, COO | A - Grant | $0.00 | +187.8K | 782.1K | +32% | $0 | |
| 2023-03-28 | 2023-03-24 | PYXS | Civik Thomas | Dir | A - Grant | $0.00 | +139.4K | 206.2K | +209% | $0 | |
| DM | 2023-03-28 | 2023-03-24 | PYXS | Wadhane Jitendra | CAO | A - Grant | $0.00 | +74.4K | 88.6K | +522% | $0 |
| 2023-03-28 | 2023-03-24 | PYXS | Cline Darren S | Dir | A - Grant | $0.00 | +139.4K | 216.2K | +181% | $0 | |
| 2023-03-28 | 2023-03-24 | PYXS | HUMPHREY RACHEL | Dir | A - Grant | $0.00 | +58.1K | 58.1K | New | $0 | |
| 2023-03-28 | 2023-03-24 | PYXS | Lewis-Hall Freda C | Dir | A - Grant | $0.00 | +139.4K | 206.2K | +209% | $0 | |
| 2023-03-28 | 2023-03-24 | PYXS | FLAVIN JOHN L | Dir | A - Grant | $0.00 | +139.4K | 377.8K | +58% | $0 | |
| D | 2023-03-28 | 2023-03-24 | PYXS | Yanchik Connealy Pamela | CFO, COO | A - Grant | $0.00 | +209.8K | 594.3K | +55% | $0 |
| D | 2023-03-28 | 2023-03-24 | PYXS | Sullivan Lara | Pres, CEO, Dir | A - Grant | $0.00 | +703.4K | 2.16M | +48% | $0 |
| D | 2023-03-28 | 2023-03-24 | PYXS | Feingold Jay | Chief Medical Off | A - Grant | $0.00 | +209.8K | 730.3K | +40% | $0 |
| A | 2023-03-23 | 2023-03-17 | PYXS | PFIZER INC | 10% | P - Purchase | $2.76 | +1.81M | 5.95M | +44% | +$5.00M |
| 2023-03-21 | 2023-03-17 | PYXS | PFIZER INC | 10% | P - Purchase | $2.76 | +1.81M | 5.95M | +44% | +$5.00M | |
| 2023-01-03 | 2023-01-03 | PYXS | Sullivan Lara | CEO, Dir | A - Grant | $0.00 | +95.7K | 1.45M | +7% | $0 | |
| 2023-01-03 | 2023-01-03 | PYXS | Yanchik Connealy Pamela | CFO | A - Grant | $0.00 | +43.5K | 384.5K | +13% | $0 | |
| 2023-01-03 | 2023-01-03 | PYXS | Feingold Jay | Chief Medical Off | A - Grant | $0.00 | +53.9K | 520.5K | +12% | $0 | |
| I | 2022-04-25 | 2022-04-21 | PYXS | Chin Mark | Former Dir | S - Sale | $3.05 | -1.75M | 0 | -100% | -$5.32M |
| 2022-04-15 | 2022-04-14 | PYXS | Yanchik Connealy Pamela | CFO | A - Grant | $0.00 | +93.5K | 341.0K | +38% | $0 | |
| 2022-04-15 | 2022-04-14 | PYXS | Sullivan Lara | CEO, Dir | A - Grant | $0.00 | +315.3K | 1.36M | +30% | $0 | |
| 2022-04-15 | 2022-04-14 | PYXS | Feingold Jay | Chief Medical Off | A - Grant | $0.00 | +115.9K | 466.6K | +33% | $0 | |
| 2022-04-04 | 2022-03-31 | PYXS | Chin Mark | Dir | A - Grant | $0.00 | +66.8K | 66.8K | New | $0 | |
| 2022-04-04 | 2022-03-31 | PYXS | Sullivan Lara | CEO, Dir | A - Grant | $0.00 | +742.6K | 1.04M | +249% | $0 | |
| 2022-04-04 | 2022-03-31 | PYXS | Lewis-Hall Freda C | Dir | A - Grant | $0.00 | +66.8K | 66.8K | New | $0 | |
| 2022-04-04 | 2022-03-31 | PYXS | FLAVIN JOHN L | Dir | A - Grant | $0.00 | +66.8K | 238.4K | +39% | $0 | |
| 2022-04-04 | 2022-03-31 | PYXS | Yanchik Connealy Pamela | CFO | A - Grant | $0.00 | +247.5K | 247.5K | New | $0 | |
| 2022-04-04 | 2022-03-31 | PYXS | Civik Thomas | Dir | A - Grant | $0.00 | +66.8K | 66.8K | New | $0 | |
| 2022-04-04 | 2022-03-31 | PYXS | Feingold Jay | Chief Medical Off | A - Grant | $0.00 | +306.9K | 350.7K | +702% | $0 | |
| 2022-04-04 | 2022-03-31 | PYXS | Cline Darren S | Dir | A - Grant | $0.00 | +66.8K | 76.8K | +668% | $0 | |
| 2021-12-09 | 2021-12-08 | PYXS | Cline Darren S | Dir | P - Purchase | $9.39 | +10.0K | 10.0K | New | +$93.9K | |
| I | 2021-11-19 | 2021-11-18 | PYXS | Civik Thomas | Dir | P - Purchase | $12.74 | +15.7K | 15.7K | New | +$200.0K |
| DI | 2021-10-15 | 2021-10-13 | PYXS | Cormorant Asset Management, LP | Former 10% Owner | P - Purchase | $16.00 | +450.0K | 1.12M | +67% | +$7.20M |
| DI | 2021-10-15 | 2021-10-13 | PYXS | Cormorant Asset Management, LP | Former 10% Owner | C - Cnv Deriv | — | +668.9K | 668.9K | New | — |
| DI | 2021-10-15 | 2021-10-13 | PYXS | Chin Mark | Dir | P - Purchase | $16.00 | +312.5K | 1.75M | +22% | +$5.00M |
| DI | 2021-10-15 | 2021-10-13 | PYXS | Chin Mark | Dir | C - Cnv Deriv | — | +1.43M | 1.43M | New | — |
| D | 2021-10-15 | 2021-10-13 | PYXS | FLAVIN JOHN L | Dir | C - Cnv Deriv | — | +2,388 | 171.6K | +1% | — |
| D | 2021-10-15 | 2021-10-13 | PYXS | Bayer World Investments B.V. | Former 10% Owner | C - Cnv Deriv | — | +2.74M | 2.74M | New | — |
| D | 2021-10-12 | 2021-10-07 | PYXS | Feingold Jay | Chief Medical Off | A - Grant | $0.00 | +43.8K | 43.8K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations